Control of Glycoprotein Synthesis. The Use of Oligosaccharide Substrates and HPLC to Study the Sequential Pathway for N-acetylglucosaminyltransferases I, II, III, IV, V, and VI in the Biosynthesis of Highly Branched N-glycans by Hen Oviduct Membranes
Overview
Cell Biology
Authors
Affiliations
Glycoproteins isolated from hen oviduct contain highly branched asparagine-linked oligosaccharides (N-glycans). Six N-acetylglucosaminyltransferases (GlcNAc-T I, II, III, IV, V, and VI) are involved in initiating the synthesis of these branches, as indicated below: (formula; see text) where R is GlcNAc beta 1----4(+/-Fuc alpha 1----6)GlcNAcAsn-X. HPLC has been used to study the substrate specificities of these GlcNAc-T and the sequential pathways involved in the biosynthesis of highly branched N-glycans in hen oviduct. Oligosaccharides with free reducing GlcNAc termini were prepared from various glycoproteins by hydrazinolysis-re-N-acetylation and used as GlcNAc-T substrates and HPLC standards. Enzyme assay components were separated on AG1 x 8, followed by HPLC on amine-bonded silica columns eluted with acetonitrile-water mixtures. Absorbance at 195 nm and radioactivity of eluted compounds were monitored. Substrates and products were identified by comparison of their retention times with those of oligosaccharides with known structures. Enzyme assay by HPLC is more rapid and convenient than previous GlcNAc-T assays using lectin columns or electrophoresis. Since some substrates yielded multiple products, these could be used to assay more than one GlcNAc-T in the same incubation. GlcNAc-T VI was shown to act on both bisected and nonbisected GlcNAc-terminating tetraantennary oligosaccharide substrates; GlcNAc-T II, IV, and V acted poorly or not at all on bisected substrates. GlcNAc-T V was the only enzyme among the six transferases studied that could be assayed in the absence of Mn2+.
A Bioorthogonal Precision Tool for Human -Acetylglucosaminyltransferase V.
Liu Y, Bineva-Todd G, Meek R, Mazo L, Piniello B, Moroz O J Am Chem Soc. 2024; 146(39):26707-26718.
PMID: 39287665 PMC: 11450819. DOI: 10.1021/jacs.4c05955.
Abdelbary M, Nolz J Immunometabolism (Cobham). 2023; 5(4):e00035.
PMID: 38027254 PMC: 10662610. DOI: 10.1097/IN9.0000000000000035.
Modulating antibody effector functions by Fc glycoengineering.
Garcia-Alija M, Van Moer B, Sastre D, Azzam T, Du J, Trastoy B Biotechnol Adv. 2023; 67:108201.
PMID: 37336296 PMC: 11027751. DOI: 10.1016/j.biotechadv.2023.108201.
Structure-based design of UDP-GlcNAc analogs as candidate GnT-V inhibitors.
Vibhute A, Tanaka H, Mishra S, Osuka R, Nagae M, Yonekawa C Biochim Biophys Acta Gen Subj. 2022; 1866(6):130118.
PMID: 35248671 PMC: 9947920. DOI: 10.1016/j.bbagen.2022.130118.
Ohkawa Y, Harada Y, Taniguchi N Biochem Soc Trans. 2021; 49(1):441-453.
PMID: 33616615 PMC: 7924997. DOI: 10.1042/BST20200780.